An overview of stereotactic body radiation therapy for hepatocellular carcinoma
Expert Review of Gastroenterology and Hepatology Volume 14 Issue 4
Page 271-279
published_at 2020-03-30
アクセス数 : 343 件
ダウンロード数 : 201 件
今月のアクセス数 : 7 件
今月のダウンロード数 : 6 件
この文献の参照には次のURLをご利用ください : https://ir.lib.hiroshima-u.ac.jp/00051079
File |
ExpRevGastroHepatol_14_271.pdf
500 KB
種類 :
fulltext
|
Title ( eng ) |
An overview of stereotactic body radiation therapy for hepatocellular carcinoma
|
Creator |
Takahashi Sigeo
Kubo Katsumaro
Imano Nobuki
Nishibuchi Ikuno
Kenjo Masahiro
|
Source Title |
Expert Review of Gastroenterology and Hepatology
|
Volume | 14 |
Issue | 4 |
Start Page | 271 |
End Page | 279 |
Abstract |
Introduction: According to several guidelines, stereotactic body radiation therapy (SBRT) for early hepatocellular carcinoma (HCC) can be considered an alternative to other modalities, such as resection, radiofrequency ablation (RFA), and transarterial chemoembolization (TACE), or when these therapies have failed or are contraindicated. This article reviews the current status of SBRT for the treatment of HCC.
Areas covered: From the results of many retrospective reports, SBRT is a promising modality with an excellent local control of almost 90% at 2–3 years and acceptable toxicities. Currently there are no randomized trials to compare SBRT and other modalities, such as resection, RFA, and TACE, but many retrospective reports and propensity score matching have shown that SBRT is comparable to the different modalities. Repeated SBRT for intra-hepatic recurrent HCC also resulted in high local control with safety and satisfactory overall survival, which were comparable to those of other curative local treatments. Expert opinion: Despite the good results of SBRT, the conclusions of the comparisons of SBRT and other modalities are still controversial. Further studies, including randomized phase III studies to define that patients are more suitable for each curative local treatment, are needed. |
Keywords |
Stereotactic body radiotherapy (SBRT)
hepatocellular carcinoma (HCC)
resection
radiofrequency ablation (RFA)
transarterial chemoembolization (TACE)
|
Language |
eng
|
Resource Type | journal article |
Publisher |
Taylor and Francis
|
Date of Issued | 2020-03-30 |
Rights |
This is an Accepted Manuscript of an article published by Taylor & Francis in Expert Review of Gastroenterology and Hepatology on 30 Mar 2020, available online: http://www.tandfonline.com/10.1080/17474124.2020.1744434.
This is not the published version. Please cite only the published version. この論文は出版社版ではありません。引用の際には出版社版をご確認、ご利用ください。
|
Publish Type | Author’s Original |
Access Rights | open access |
Source Identifier |
[ISSN] 1747-4124
[ISSN] 1747-4132
[DOI] 10.1080/17474124.2020.1744434
[DOI] https://doi.org/10.1080/17474124.2020.1744434
|